Oncolytic Replication of E1b-Deleted Adenoviruses

Various viruses have been studied and developed for oncolytic virotherapies. In virotherapy, a relatively small amount of viruses used in an intratumoral injection preferentially replicate in and lyse cancer cells, leading to the release of amplified viral particles that spread the infection to the surrounding tumor cells and reduce the tumor mass. Adenoviruses (Ads) are most commonly used for oncolytic virotherapy due to their infection efficacy, high titer production, safety, easy genetic modification, and well-studied replication characteristics. Ads with deletion of E1b55K preferentially replicate in and destroy cancer cells and have been used in multiple clinical trials. H101, one of the E1b55K-deleted Ads, has been used for the treatment of late-stage cancers as the first approved virotherapy agent. However, the mechanism of selective replication of E1b-deleted Ads in cancer cells is still not well characterized. This review will focus on three potential molecular mechanisms of oncolytic replication of E1b55K-deleted Ads. These mechanisms are based upon the functions of the viral E1B55K protein that are associated with p53 inhibition, late viral mRNA export, and cell cycle disruption.

• Publication year

  2015

• Venue

  Viruses

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v7112905PMID 26561828PMCID 4664978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adenovirus membrane penetration: Tickling the tail of a sleeping dragon.

  2015cited by this paper
• Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter

  2015cited by this paper
• Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice

  2015cited by this paper
• Molecular Basis for Viral Selective Replication in Cancer Cells: Activation of CDK2 by Adenovirus-Induced Cyclin E

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells

  2013cited by this paper
• ONCOLYTIC VIROTHERAPY

  2012cited by this paper
• Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus.

  2012cited by this paper
• Adenoviruses induce autophagy to promote virus replication and oncolysis.

  2011cited by this paper
• The E3 Ubiquitin Ligase Activity Associated with the Adenoviral E1B-55K–E4orf6 Complex Does Not Require CRM1-Dependent Export

  2011cited by this paper
• Adenovirus E1B 55-Kilodalton Protein Is a p53-SUMO1 E3 Ligase That Represses p53 and Stimulates Its Nuclear Export through Interactions with Promyelocytic Leukemia Nuclear Bodies

  2010cited by this paper
• Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression

  2009cited by this paper
• A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

  2009influential reference
• Oncolytic viral therapy of malignant glioma

  2009cited by this paper
• Adenovirus E1B55K Region Is Required To Enhance Cyclin E Expression for Efficient Viral DNA Replication

  2008cited by this paper
• Oncolytic virotherapy.

  2008cited by this paper
• Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer

  2008cited by this paper
• Chinese health biotech and the billion-patient market

  2008cited by this paper
• Control of mRNA Export by Adenovirus E4orf6 and E1B55K Proteins during Productive Infection Requires E4orf6 Ubiquitin Ligase Activity

  2008cited by this paper
• Clinical trials with oncolytic adenovirus in China.

  2007cited by this paper
• Adenovirus Ubiquitin-Protein Ligase Stimulates Viral Late mRNA NuclearExport

  2007cited by this paper
• Kinase-independent function of cyclin E.

  2007cited by this paper
• Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation

  2007cited by this paper
• An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

  2007cited by this paper
• Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas

  2007cited by this paper
• From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

  2007cited by this paper
• China approves world's first oncolytic virus therapy for cancer treatment.

  2006cited by this paper
• Adenovirus E1B 55-Kilodalton Protein Is Required for both Regulation of mRNA Export and Efficient Entry into the Late Phase of Infection in Normal Human Fibroblasts

  2006cited by this paper
• Gene expression profiles of normal human lung cells affected by adenoviral E1B.

  2006influential reference
• Adenoviral vectors

  2006cited by this paper
• Stepwise D ismantling of Adenovirus 2 durhg Entry into Cek llrs

  2006cited by this paper
• p53 promotes adenoviral replication and increases late viral gene expression

  2006cited by this paper
• Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.

  2005cited by this paper
• Adenoviral gene therapy, radiation, and prostate cancer.

  2005cited by this paper
• A mouse model for cyclin E-dependent genetic instability and tumorigenesis.

  2005cited by this paper
• Cyclin E in normal and neoplastic cell cycles

  2005cited by this paper
• Overexpression of adenovirus E3-11.6K protein induces cell killing by both caspase-dependent and caspase-independent mechanisms.

  2004cited by this paper
• Cyclin E.

  2004cited by this paper
• E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells

  2004influential reference
• E1B-55-Kilodalton Protein Is Not Required To Block p53-Induced Transcription during Adenovirus Infection

  2004cited by this paper
• Structural Basis for Competitive Inhibition of eIF4G-Mnk1 Interaction by the Adenovirus 100-Kilodalton Protein

  2004cited by this paper
• Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

  2004cited by this paper
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

  2004cited by this paper
• Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.

  2004influential reference
• Viral vectors for gene delivery to the nervous system

  2003cited by this paper
• Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

  2003cited by this paper
• Regulation of mRNA production by the adenoviral E1B 55-kDa and E4 Orf6 proteins.

  2003cited by this paper
• E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

  2003cited by this paper
• Cyclin E and survival in patients with breast cancer.

  2002cited by this paper
• p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation.

  2002cited by this paper
• Viral oncolysis.

  2002cited by this paper
• The Oncogenic Activity of Cyclin E Is Not Confined to Cdk2 Activation Alone but Relies on Several Other, Distinct Functions of the Protein*

  2002cited by this paper
• Adenovirus and cell cycle control.

  2002cited by this paper
• Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes

  2002cited by this paper
• Bak and Bax Function To Limit Adenovirus Replication through Apoptosis Induction

  2002cited by this paper
• Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

  2002cited by this paper
• Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

  2001cited by this paper
• Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line

  2001cited by this paper
• Cyclin E mRNA Overexpression in Epithelial Ovarian Cancers: Inverse Correlation with p53 Protein Accumulation

  2001cited by this paper
• Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.

  2001cited by this paper
• Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway?

  2001cited by this paper
• Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

  2001cited by this paper
• Arenaviridae: The viruses and their replication

  2001influential reference
• Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

  2001cited by this paper
• Adenovirus‐specific translation by displacement of kinase Mnk1 from cap‐initiation complex eIF4F

  2000cited by this paper
• Adenoviral vectors.

  2000cited by this paper
• E1B 55-Kilodalton Oncoproteins of Adenovirus Types 5 and 12 Inactivate and Relocalize p53, but Not p51 or p73, and Cooperate with E4orf6 Proteins To Destabilize p53

  2000cited by this paper
• Induction of apoptosis by adenovirus E4orf4 protein

  2000cited by this paper
• Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53.

  2000cited by this paper
• ONYX-015 selectivity and the p14ARF pathway

  2000cited by this paper
• Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)

  2000cited by this paper
• Translation by ribosome shunting on adenovirus and hsp70 mRNAs facilitated by complementarity to 18S rRNA.

  2000cited by this paper
• Roles for the E4 orf6, orf3, and E1B 55-Kilodalton Proteins in Cell Cycle-Independent Adenovirus Replication

  1999influential reference
• Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex

  1999cited by this paper
• Cyclin E in human cancers

  1999cited by this paper
• Deregulated cyclin E induces chromosome instability

  1999cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998cited by this paper
• Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells

  1998cited by this paper
• Stabilization of p53 by Adenovirus E1A Occurs through Its Amino-terminal Region by Modification of the Ubiquitin-Proteasome Pathway*

  1998cited by this paper
• p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection

  1998cited by this paper
• Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression

  1998cited by this paper
• Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress

  1998cited by this paper
• Adenovirus E1B 55K Represses p53 Activation In Vitro

  1998cited by this paper
• The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle

  1997cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function.

  1997cited by this paper
• The significance of p53 mutations in human cancers.

  1996cited by this paper
• Induction of the

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Human cyclin E, a nuclear protein essential for the G1-to-S phase transition

  1995cited by this paper
• Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure.

  1994cited by this paper
• Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

  1993cited by this paper
• Stepwise dismantling of adenovirus 2 during entry into cells.

  1993cited by this paper
• Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.

  1993cited by this paper
• The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins.

  1992influential reference
• The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Transactivation of the p53 oncogene by E1a gene products.

  1990cited by this paper
• Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

  1990cited by this paper
• The adenovirus L4 100-kilodalton protein is necessary for efficient translation of viral late mRNA species

  1990cited by this paper

• Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

  2026cites this paper
• Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest

  2026cites this paper
• Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances

  2025cites this paper
• Cancer genetics and response to oncolytic virus treatment for ovarian cancer

  2025cites this paper
• Oncolytic Virotherapy in Solid Tumors: A Current Review

  2025cites this paper
• Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review)

  2025cites this paper
• New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

  2024cites this paper
• Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry

  2024cites this paper
• Development of a recombinant non-replicating Newcastle disease virus

  2024cites this paper
• Gene and cell therapy of human genetic diseases: Recent advances and future directions

  2024cites this paper
• Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives

  2024cites this paper
• Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner

  2024cites this paper
• Current status and research progress of oncolytic virus

  2024cites this paper
• Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review

  2024cites this paper
• Cancer immunotherapies: A hope for the uncurable?

  2023cites this paper
• Rational selection of an ideal oncolytic virus to address current limitations in clinical translation.

  2023cites this paper
• Development and application of oncolytic viruses as the nemesis of tumor cells

  2023cites this paper
• Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy

  2023cites this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cites this paper
• Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study

  2022cites this paper
• Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients

  2022cites this paper
• Ixovex-1, a novel oncolytic E1B-mutated adenovirus

  2022cites this paper
• Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses

  2022cites this paper
• Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

  2022cites this paper
• E1B-55K Is a Phosphorylation-Dependent Transcriptional and Posttranscriptional Regulator of Viral Gene Expression in Human Adenovirus C5 Infection

  2022cites this paper
• A potential bat adenovirus-based oncolytic virus targeting canine cancers

  2021cites this paper
• Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein

  2021cites this paper
• Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response

  2021cites this paper
• Oncolytic adenoviral H101 synergizes with radiation in cervical cancer cells.

  2021cites this paper
• Almost famous: Human adenoviruses (and what they have taught us about cancer)

  2021cites this paper
• The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis

  2021influential citation
• The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

  2021cites this paper
• Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy

  2021cites this paper
• Current Applications of Pharmaceutical Biotechnology

  2020cites this paper
• Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies

  2020cites this paper
• A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma

  2020cites this paper
• Multilevel Targeting of Canine Adenovirus Type 2 (CAV2) to Expand Oncolytic Virotherapy in Canine Tumors

  2020cites this paper
• Oncolytic Viruses as Immunotherapeutic Agents

  2020cites this paper
• Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy

  2020cites this paper
• Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer

  2020cites this paper
• Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

  2020cites this paper
• The Important Role of Oncolytic Viruses in Common Cancer Treatments

  2020cites this paper
• Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

  2019influential citation
• Gene Therapy.

  2019cites this paper
• Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy

  2019cites this paper
• Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.

  2019cites this paper
• Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

  2018cites this paper
• Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches

  2018influential citation
• NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses—Therapeutic Perspectives

  2018cites this paper
• The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

  2018cites this paper
• The advent of oncolytic virotherapy in oncology: The Rigvir® story

  2018cites this paper
• Integrating oncolytic viruses in combination cancer immunotherapy

  2018cites this paper
• Fighting Cancer with Viruses: Oncolytic Virus Therapy in China

  2017cites this paper
• Recent advances in genetic modification of adenovirus vectors for cancer treatment

  2017cites this paper
• From Benchtop to Bedside: A Review of Oncolytic Virotherapy

  2016cites this paper
• Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer Selection

  2016cites this paper
• Adenovirus with DNA Packaging Gene Mutations Increased Virus Release

  2016cites this paper